Development of monoclonal antibodies targeting Her-2 and EGFR in the treatment of breast cancer

Abstract

Breast cancer is the highest incidence of female cancer malignant tumors, the global incidence of breast cancer is about 12%, and the mortality rate is about 7%. For patients with breast cancer, surgery, radiotherapy, chemotherapy, targeted therapy, endocrine therapy, and immunotherapy are often used. Throughout history, monoclonal antibodies have revolutionized the breast cancer treatment patients. Her-2 and EGFR antibodies have been particularly important. Cetuximab and panizumab can block EGFR ligand binding, thereby preventing EGFR from functioning. Trastuzumab and pertuzumab are anti-Her-2 monoantibodies that have been clinically proven to be effective. Although endocrine therapy and anti-Her-2 targeted therapy have achieved certain results, these treatments are effective for all patients and have certain side effects. This paper examines the effects of five specific monoclonal antibodies on breast cancer, including benefits, drawbacks, and side effects, using clinical trial materials and academic papers published since 2001. This paper emphasizes Her-2 antibodies and breast cancer, as well as the role of specific Her-2 and EGFR antibodies.